DARZALEX FASPRO
PeakmAbBLAINJECTIONINJECTABLE
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
DARZALEX FASPRO by Johnson & Johnson is cd38 is a transmembrane glycoprotein (48 kda) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (al) amyloidosis, as well as other cell types. Approved for lenalidomide, dexamethasone for induction, consolidation in newly diagnosed patients and 11 more indications. First approved in 2020.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARZALEX FASPRO is a CD38-directed monoclonal antibody combined with recombinant human hyaluronidase designed for subcutaneous administration, enabling faster infusion than intravenous formulations. It treats multiple myeloma and other CD38-expressing hematologic malignancies by triggering immune-mediated cytolysis of cancer cells. The hyaluronidase component enhances subcutaneous bioavailability and reduces administration time, improving patient convenience and clinical workflow.
$0.070BPart D
PeakStable
Peak-stage product with $70M Part D spending signals a mature, well-established commercial organization requiring cross-functional expertise in market maintenance and competitor defense.
Mechanism of Action
CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 has multiple functions, including receptor mediated adhesion, signaling, and…
Indications (14)
Worked on DARZALEX FASPRO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.